Bruce Forrest possesses over 30 years of global leadership in pharmaceutical development with speciality expertise in, but not limited to, vaccines and biopharmaceuticals development in both major and emerging markets. Combine this with recent experience as an Investment Banker, and an established a reputation for innovative solutions to complex product development challenges through a broad perspective and understanding of the pharmaceutical industry, banking and financing, and the need to have organizational alignment across development, manufacturing, and commercial activities to drive success.In addition, Bruce Forrest has extensive experience and field knowledge of the pharmaceutical development environment in Asia, especially Japan, where he served as Board Member, Corporate Officer and Executive Director (Head) of R&D for Wyeth K.K. He oversaw the local product approvals for etanercept and gemtuzumab ozogamicin, as well as product registration submissions for a pneumococcal conjugate vaccine, bazedoxifene, temsirolimus, venlafaxine and tigecycline; and, was responsible for developing a successful strategy for the integration and coordination of development activities across the major markets in East Asia. During his career in the pharmaceutical and medical device industry, Bruce Forrest was the clinical leader for several major vaccine programs, including: a meningococcal C conjugate vaccine; a live, rotavirus vaccine; a pneumococcal conjugate vaccine; and, live attenuated influenza vaccine. As a Senior Vice President at Wyeth Pharmaceuticals, Bruce Forrest was responsible for all late phase development activities in Wyeth Vaccines Research leading both clinical and pharmaceutical science development, including Fermentation and Process Development, Analytical Development, Formulation Development, GMP testing, Development Project Management, GMP Clinical Supplies Manufacturing and Distribution, Outsourcing Management, and Development Finance.